Drug Treatment Attenuates Retinal Ganglion Cell Death by Inhibiting Collapsin Response Mediator Protein 2 Phosphorylation in Mouse Models of Normal Tension Glaucoma
NeuroMolecular Medicine · 2024
DOI: 10.1007/s12017-024-08778-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift NeuroMolecular Medicine, 2024. Verfasst von Yuebing Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Science and Medical Bioscience, Waseda University, Shinjuku-ku, Tokyo, 162-8480, Japan. Hauptthemen laut MEDLINE: Alkaloids, Glaucoma, Glaucoma, Open-Angle, Low Tension Glaucoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Normal tension glaucoma (NTG) is a progressive neurodegenerative disease in glaucoma families. Typical glaucoma develops because of increased intraocular pressure (IOP), whereas NTG develops despite normal IOP. As a subtype of open-angle glaucoma, NTG is characterized by retinal ganglion cell (RGC) degeneration, gradual loss of axons, and injury to the optic nerve. The relationship between glutamate excitotoxicity and oxidative stress has elicited great interest in NTG studies. We recently reported that suppressing collapsin response mediator protein 2 (CRMP2) phosphorylation in S522A CRMP2 mutant (CRMP2 KIKI) mice inhibited RGC death in NTG mouse models. This study evaluated the impact of the natural compounds huperzine A (HupA) and naringenin (NAR), which have therapeutic effects against glutamate excitotoxicity and oxidative stress, on inhibiting CMRP2 phosphorylation in mice intravitreally injected with N -methyl- d -aspartate (NMDA) and GLAST mutant mice. Results of the study demonstrated that HupA and NAR significantly reduced RGC degeneration and thinning of the inner retinal layer, and inhibited the elevated CRMP2 phosphorylation. These treatments protected against glutamate excitotoxicity and suppressed oxidative stress, which could provide insight into developing new effective therapeutic strategies for NTG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Life Science and Medical Bioscience, Waseda University, Shinjuku-ku, Tokyo, 162-8480, Japan.
- Nara Medical University, Kashihara City, Nara, 634-8521, Japan.
- Department of Molecular Pharmacology and Neurobiology, Yokohama City University Graduate School of Medicine, Yokohama, 236-0004, Japan.
- Visual Research Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, 156-8506, Japan.
- Laboratory for Molecular Brain Science, Department of Life Science and Medical Bioscience, Waseda University, 2-2 Wakamatsu-cho, Shinjuku-ku, Tokyo, 162-8480, Japan. ohshima@waseda.jp.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Wang, Y., Brahma, M. M., Takahashi, K., Hernandez, A. N. B., Ichikawa, K., Minami, S., Goshima, Y., Harada, T., & Ohshima, T. (2024). Drug Treatment Attenuates Retinal Ganglion Cell Death by Inhibiting Collapsin Response Mediator Protein 2 Phosphorylation in Mouse Models of Normal Tension Glaucoma. NeuroMolecular Medicine. https://doi.org/10.1007/s12017-024-08778-1
Vancouver
Wang Y, Brahma MM, Takahashi K, Hernandez ANB, Ichikawa K, Minami S, et al. Drug Treatment Attenuates Retinal Ganglion Cell Death by Inhibiting Collapsin Response Mediator Protein 2 Phosphorylation in Mouse Models of Normal Tension Glaucoma. NeuroMolecular Medicine. 2024. doi:10.1007/s12017-024-08778-1
BibTeX
@article{Wang2024,
author = {Wang, Yuebing and Brahma, Musukha Mala and Takahashi, Kazuya and Hernandez, Alessandra Nolia Blanco and Ichikawa, Koki and Minami, Syuntaro and Goshima, Yoshio and Harada, Takayuki and Ohshima, Toshio},
title = {Drug Treatment Attenuates Retinal Ganglion Cell Death by Inhibiting Collapsin Response Mediator Protein 2 Phosphorylation in Mouse Models of Normal Tension Glaucoma},
journal = {NeuroMolecular Medicine},
year = {2024},
doi = {10.1007/s12017-024-08778-1}
}
EUVIMED